Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Current intelligence bulletin 12 - diethylcarbamoyl chloride (DECC).

Authors
NIOSH
Source
NIOSH 1976 Jul; :1
NIOSHTIC No.
00170793
Abstract
This Current Intelligence Bulletin (CIB) briefly presents information on the genotoxic hazards associated with diethylcarbamoyl-chloride (88108) (DECC). A study of the mutagenic potential of DECC found that it was mutagenic in two strains of Escherichia-coli, (WP-2) and (WP-2S). DECC, however, was not as potent a mutagen as the closely related analog dimethylcarbamoyl- chloride (79447) (DMCC). DMCC was found to have carcinogenic activity in laboratory animals after subcutaneous, intraperitoneal, and inhalation exposure, as noted in another NIOSH CIB. Annual production of DECC in recent years amounted to less than 15000 pounds. The only known commercial use of DECC in the United States was as an intermediate in the synthesis of diethylcarbamazine- citrate, a pharmaceutical used as an anthelmintic (worming agent). Diethylcarbamazine-citrate is said to be produced and marketed as Hetrazan and Caricide by Lederle Laboratories, a division of the American Cyanamide Company.
Keywords
NIOSH-Current-Intelligence-Bulletin-No-12; Organic-compounds; Mutagenesis; Bioassays; Microbial-test-systems; Risk-analysis; Health-hazards; Genetics; Chemical-synthesis
CAS No.
88-10-8; 79-44-7
Publication Date
19760707
Document Type
Numbered Publication; Current Intelligence Bulletin
Fiscal Year
1976
NTIS Accession No.
NTIS Price
Identifying No.
(NIOSH) 78-127; CIB 12
Source Name
National Institute for Occupational Safety and Health
State
OH
TOP